Share
سرطان الثدي عند النساء العراقيات من نوع HER2 +VE مع الفائدة من استخدام العقار المناعي Trastuzumzb بعد الانتكاسه السريريه لاستخدامه == Her2 positive Iraqi breast cancer women Use of trastuzumab beyond progression
Author name:
وليد جاسم محمد
Supervisor name:
منور عبد الاله النقاش
General topic:
Medicine
Specific topic:
Therapeutic Radiology
Degree:
Higher Diploma
University:
University of Baghdad - Faculty Of Medicine
Language:
English
University location:
Baghdad
First pages:
19T1637 - p.pdf
Abstract:
Background : Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Her 2 positive disease carries worse prognosis and anti her 2 therapy is required in addition to chemotherapy which increase the cost of management of those patients especially in metastatic settingObjectives : The aim of this study to assess Iraqi breast cancer patients with HER2/neu molecular profile. Evaluate the role of using Trastuzumab in metastatic HER2/neu positive breast cancer patients beyond progression after its use in first line by changing the chemotherapeutic agent only.Patients & Methods : This is a retrospective study which was conducted in oncology teaching hospital - medical City complex from 1st of July 2017 to 1st of December 2017, carried out on 253 breast cancer female patients diagnosed within the period 2010 - 2017 with different age groups. Their histopathological reports, immunohistochemistry (IHC) results including ER, PR, HER2/neu and CISH test when indicated in addition to their clinical profile were collected. The subgroup of patients (253) with her2 positive disease were identified. From which patients with metastatic disease were analyzed for the use of trastuzumab beyond progression.Results : The mean age ± SD was (51.7 ± 11.1) years in HER2/neu positive patients, while it was (51.4 ± 13.8) in metastatic HER2/neu patients. The prevalence of HER2/neu positive 16.656 %( 95% CI : 16.468_16.843%). The mean of number of trastuzumab cycles used in patient that not metastatic HER2/neu was (16.6 ±3.9) and at metastatic HER2/neu was (16.1 ± 6.9). Median time to progression was 16 (95% CI : 11.009 - 20.991) months, after 6 months 92.8% had progression - free and after 12 month 53.8% had progression - free.Conclusion : HER2/neu positive disease constitutes 16.656% of Iraqi patients with breast cancer. And the median age for metastasis was (51.4 ± 13.8).Also Trastuzumab use beyond progression had a clinically significant metastatic free survival benefit. The cumulative incidence of metastasis to different body organs was lung (89.8%), liver (57.6%), and bone (45.8%), brain (27.8%).
